Document is current
Any future updates will be listed below
-
Authors
Baldanzi, Gabriel https://orcid.org/0000-0003-3962-3953
Larsson, Anna https://orcid.org/0009-0004-7016-9802
Sayols-Baixeras, Sergi
Dekkers, Koen F. https://orcid.org/0000-0002-4074-7235
Hammar, Ulf
Nguyen, Diem
Graells, Tíscar
Ahmad, Shafqat
Gazolla Volpiano, Camila
Meric, Guillaume https://orcid.org/0000-0001-6288-9958
Järhult, Josef D. https://orcid.org/0000-0002-7075-1059
Tängdén, Thomas https://orcid.org/0000-0001-7142-9849
Ludvigsson, Jonas F.
Lind, Lars
Sundström, Johan https://orcid.org/0000-0003-2247-8454
Michaëlsson, Karl
Ärnlöv, Johan
Kennedy, Beatrice
Orho-Melander, Marju https://orcid.org/0000-0002-3578-2503
Fall, Tove https://orcid.org/0000-0003-2071-5866
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 11 February 2026
First Online: 11 March 2026
Competing interests
: J.S. reports direct or indirect stock ownership in companies (Anagram Kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) that provide services not related to the present work to companies and authorities in the health sector, including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma and WeMind. J.Ä. has served on the advisory boards for Astella, AstraZeneca and Boehringer Ingelheim and has received lecturing fees from AstraZeneca and Novartis, all unrelated to the present work. J.F.L. has also received financial support from M.S.D. to develop a paper reviewing national healthcare registers in China, has ongoing discussions with M.S.D. about unrelated IBD research and receives funding for celiac disease research from Takeda. The other authors declare no competing interests.
